Similar articles for PMID: 25635138

Year	Number of Results
1949	1
1993	1
1994	1
1998	2
2001	2
2002	1
2003	1
2004	2
2005	1
2006	1
2007	3
2008	8
2009	5
2010	10
2011	14
2012	16
2013	20
2014	29
2015	37
2016	48
2017	44
2018	44
2019	42
2020	22
2021	16
2022	11
2023	6
2024	0

1

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.

Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA. Yu EY, et al. J Nucl Med. 2015 Mar;56(3):354-60. doi: 10.2967/jnumed.114.146936. Epub 2015 Jan 29. J Nucl Med. 2015. PMID: 25635138 Free PMC article. Clinical Trial.

2

Whole-Body [¹⁸F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687.

Muzi M, O'Sullivan F, Perk TG, Muzi JP, Mankoff DA, Jeraj R, Duan F, Yu EY. Muzi M, et al. Tomography. 2021 Apr 25;7(2):139-153. doi: 10.3390/tomography7020013. Tomography. 2021. PMID: 33923126 Free PMC article. Clinical Trial.

3

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.

Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Etchebehere EC, et al. J Nucl Med. 2015 Aug;56(8):1177-84. doi: 10.2967/jnumed.115.158626. Epub 2015 Jun 11. J Nucl Med. 2015. PMID: 26069307 Free article.

4

Quantitative Assessment of Early [¹⁸F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.

Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, Apolo AB, Humm JL, Larson SM, Morris MJ, Liu G, Jeraj R. Harmon SA, et al. J Clin Oncol. 2017 Aug 20;35(24):2829-2837. doi: 10.1200/JCO.2017.72.2348. Epub 2017 Jun 27. J Clin Oncol. 2017. PMID: 28654366 Free PMC article. Clinical Trial.

5

Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.

Roth AR, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, Dahut WL, Apolo AB, Morris MJ, Perlman SB, Liu G, Jeraj R. Roth AR, et al. Clin Genitourin Cancer. 2019 Aug;17(4):306-314. doi: 10.1016/j.clgc.2019.05.013. Epub 2019 May 27. Clin Genitourin Cancer. 2019. PMID: 31221545 Free PMC article.

6

Uptake of Radium-223 Dichloride and Early [¹⁸F]NaF PET Response Are Driven by Baseline [¹⁸F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients.

Letellier A, Johnson AC, Kit NH, Savigny JF, Batalla A, Parienti JJ, Aide N. Letellier A, et al. Mol Imaging Biol. 2018 Jun;20(3):482-491. doi: 10.1007/s11307-017-1132-4. Mol Imaging Biol. 2018. PMID: 29027074

7

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB. Twardowski PW, et al. Anticancer Drugs. 2013 Aug;24(7):743-53. doi: 10.1097/CAD.0b013e328361feb0. Anticancer Drugs. 2013. PMID: 23652277 Free PMC article. Clinical Trial.

8

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.

Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. Yu EY, et al. Clin Cancer Res. 2009 Dec 1;15(23):7421-8. doi: 10.1158/1078-0432.CCR-09-1691. Epub 2009 Nov 17. Clin Cancer Res. 2009. PMID: 19920114 Free PMC article. Clinical Trial.

9

Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.

Doot RK, Muzi M, Peterson LM, Schubert EK, Gralow JR, Specht JM, Mankoff DA. Doot RK, et al. J Nucl Med. 2010 Apr;51(4):521-7. doi: 10.2967/jnumed.109.070052. Epub 2010 Mar 17. J Nucl Med. 2010. PMID: 20237040 Free PMC article. Clinical Trial.

10

Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.

Maines F, Caffo O, Donner D, Sperduti I, Bria E, Veccia A, Chierichetti F, Tortora G, Galligioni E. Maines F, et al. Future Oncol. 2016 Feb;12(3):333-42. doi: 10.2217/fon.15.277. Epub 2016 Jan 15. Future Oncol. 2016. PMID: 26768648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

331 results

Results by year